Senti Biosciences, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $0.10
- 52-Week Range
- $0.09 – $95.04
- Market Cap
- $225.95K
- P/E (TTM)
- —
- EPS (TTM)
- -46.20
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- —
- PEG Ratio
- —
- Return on Equity
- —
- Return on Assets
- -71.16%
- Gross Margin
- 0.00%
- Operating Margin
- -62343.24%
- Profit Margin
- 0.00%
- Current Ratio
- 0.54
- Debt/Equity
- —
- Total Debt
- $21.56M
- Free Cash Flow
- $-21.57M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $262.07M
Market Snapshot
About
Senti Biosciences is a clinical-stage biotechnology company developing next-generation cell and gene therapies using synthetic biology. The company designs programmable cellular therapies that can sense disease-specific signals and respond with precision therapeutic action. Senti is advancing multiple programs in oncology and immunology.